Abstract | PURPOSE: PATIENTS AND METHODS: Between December 1987 and April 1993, 39 patients with all stages of MF and SS were treated with combined phototherapy and systemic interferon alfa-2a as part of two institutional studies. The initial phase I study of 15 patients established the maximum-tolerated dose of interferon and has been previously reported. Subsequently, 24 patients have been entered onto a phase II trial. Long-term follow-up data are provided for both studies. RESULTS: The median follow-up duration for the entire cohort is 28 months. Patients with all stages of disease were enrolled (stage IB, n = 14; IIA, n = 5; IIB, n = 6; III, n = 8; IVA, n = 5; IVB, n = 1). Thirty-four patients had received previous therapy. Overall, 36 of 39 patients achieved a complete response (CR; 62%) or partial response (28%) to therapy. The median response duration is 28 months (range, 1 to 64). Twenty-nine of 39 patients are alive, with a median survival duration of 62 months (range, 1 to 66). CONCLUSION:
|
Authors | T M Kuzel, H H Roenigk Jr, E Samuelson, J J Herrmann, A Hurria, A W Rademaker, S T Rosen |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 13
Issue 1
Pg. 257-63
(Jan 1995)
ISSN: 0732-183X [Print] United States |
PMID | 7799028
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
|
Topics |
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Humans
- Interferon alpha-2
- Interferon-alpha
(adverse effects, therapeutic use)
- Male
- Mycosis Fungoides
(mortality, therapy)
- PUVA Therapy
- Recombinant Proteins
- Sezary Syndrome
(mortality, therapy)
- Skin Neoplasms
(mortality, therapy)
- Survival Analysis
|